Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Pharmaceutical composition containing prostaglandin

A technology of prostaglandin and composition, which is applied in the field of pharmaceutical composition of oil-in-water emulsion, can solve the problem of content decline and achieve the effect of inhibiting decomposition

Inactive Publication Date: 2009-05-06
SENJU PHARMA CO LTD
View PDF9 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, when the derivatives of prostaglandins are made into water-based liquid preparations, generally, it must be considered that prostaglandins and their derivatives are difficult to dissolve in water, or they are easily decomposed once dissolved in water, and then the content of the prostaglandin and its derivatives is caused by adsorption to the container. drop etc.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Pharmaceutical composition containing prostaglandin

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0076] [Formulation Example 1] Eye Drops

[0077] Latanoprost 0.01g

[0078] Concentrated Glycerin 2.4g

[0079] Polyvinyl alcohol 2g

[0080] Sodium acetate 0.1g

[0081] Sodium edetate 0.01g

[0082] Chlorhexidine Gluconate Solution (20W / V%) 0.025mL

[0083] ミダリオ—ル812 1g

[0084] Hydrochloric acid amount

[0085] Purified water The total volume becomes 100mL

[0086] pH 7.0

[0087] According to the above prescription, disperse concentrated glycerin and polyvinyl alcohol in an aqueous solution of sodium acetate, heat it, and dissolve it while vigorously stirring with a homomixer, then add migelio-lu dissolved in latanoprost to make it emulsified. Cool to room temperature, add edetate sodium, chlorhexidine gluconate solution, add 1N hydrochloric acid to adjust the pH, mix well, filter and sterilize to prepare eye drops.

Embodiment 2

[0088] [Formulation Example 2] Eye Drops

[0089] Latanoprost 0.005g

[0090] Concentrated Glycerin 2.4g

[0091] Boric acid 1.6g

[0092] Sodium edetate 0.01g

[0093] Sorbic acid 0.2g

[0094] Hydroxypropyl methylcellulose 0.9g

[0095] ミゲリオ—ル812 0.6g

[0096] Hydrochloric acid amount

[0097] Purified water The total volume becomes 100mL

[0098] pH 7.0

[0099] According to the above prescription, slowly disperse concentrated glycerin and hydroxypropyl methylcellulose in the boric acid aqueous solution, heat, and dissolve while vigorously stirring with a homomixer, then add the latanoprost-dissolved ミゲリオール, make of emulsification. Cool to room temperature, add sodium edetate, sorbic acid, and hydrochloric acid to adjust the pH, mix well, filter and sterilize to prepare eye drops.

Embodiment 3

[0100] [Formulation Example 3] Eye Drops

[0101] Latanoprost 0.005g

[0102] Concentrated Glycerin 2.4g

[0103] Sodium acetate 0.1g

[0104] Sodium edetate 0.01g

[0105] Sorbic acid 0.2g

[0106] Xanthan gum 0.9g

[0107] Peanut protein oil 0.6g

[0108] Hydrochloric acid amount

[0109] Purified water The total volume becomes 100mL

[0110] pH 6.0

[0111] According to the above prescription, slowly disperse concentrated glycerin and xanthan gum in an aqueous solution of sodium acetate, heat, dissolve while vigorously stirring with a homomixer, and then add Migliol in which latanoprost is dissolved to emulsify it. Cool to room temperature, add sodium edetate, sorbic acid, and 1N hydrochloric acid to adjust the pH, mix well, filter and sterilize to prepare eye drops.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
particle diameteraaaaaaaaaa
Login to View More

Abstract

An object of the present invention is to provide a stable aqueous pharmaceutical composition which suppresses degradation of prostaglandin F 2 alpha in a preparation containing prostaglandin F 2alpha. The object was attained by formulating a prostaglandin F 2alpha derivative into an oil-in-water emulsion together with an oil, for example, medium chain fatty acid triglyceride, a water-soluble polymer and water.

Description

technical field [0001] The present invention relates to is containing prostaglandin F 2α Pharmaceutical composition of oil-in-water emulsion formed by derivative, oil, water-soluble polymer and water and inhibition of prostaglandin F in the composition 2α method of decomposition. Background technique [0002] Prostaglandins are physiologically active substances derived from polyunsaturated fatty acids. Because they have various important pharmacological and physiological effects in small amounts, they are synthesized into various derivatives for medical use. For example, prostaglandin F 2α Derivatives of the product are useful as a therapeutic agent for cataract and ocular hypertension, and several eye drops have been developed and marketed. However, when the derivatives of prostaglandins are made into water-based liquid preparations, generally, it must be considered that prostaglandins and their derivatives are difficult to dissolve in water, or they are easily decompose...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Patents(China)
IPC IPC(8): A61K31/5575A61K9/107A61K47/32A61K47/38A61K47/36A61K47/44A61P27/02A61P27/06A61K9/00
CPCA61K9/0048A61K31/5575A61P27/02A61P27/06A61K9/113
Inventor 境祐辅大鸟聪
Owner SENJU PHARMA CO LTD
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com